Oxigene Logo spacer
Learn More Graphic
Developing the next generation of VDAs

OXiGENE is a biopharmaceutical company whose mission is finding and developing new and improved therapeutics that can deliver significant medical benefits to patients with cancer and sight-threatening eye diseases and conditions.

Latest News and Press

Thursday, June 25, 2009
OXiGENE Initiates Phase 2 Trial of ZYBRESTAT for Ophthalmology

Wednesday, June 17, 2009
OXiGENE Appoints Dr. Peter J. Langecker as Chief Development Officer

 
Pipeline
spacer Stock Quote Graphic spacer
More Button
 
Clinical Trials
spacer spacer

FACT

FALCON

Ovarian Cancer

OXi4503

spacer
More Button
Message to our Stockholders